Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11060-008-9764-5.pdf
Reference22 articles.
1. Brada M, Hoang-Xuang K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266. doi: 10.1023/A:1008382516636
2. Brandes AA, Ermani M, Basso U et al (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63(1):38–41. doi: 10.1159/000065718
3. Kappelle AC, Postma TJ, Taphoorn MJ et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56:118–120
4. Wick W, Steinbach JP, Küker WM et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115
5. Yung WK (2002) Temozolomide in malignant gliomas. Semin Oncol 27(3–6):27–34
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database;Frontiers in Pharmacology;2024-08-23
2. Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management;Journal of Neuro-Oncology;2023-03
3. Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma;Japanese Journal of Clinical Oncology;2022-07-21
4. Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms;Journal of Neuroendocrinology;2022-07
5. Granulocyte-macrophage colony-stimulating factor enhances effect of temozolomide on high-grade glioma cells;Anti-Cancer Drugs;2020-06-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3